Pherecydes Pharma
Pherecydes Pharma is a French private biotech developing precision phage therapy for antibiotic-resistant bacterial infections, primarily targeting resistant E. coli for hospital and healthcare use. It collaborates with CEA and is funded by venture capital and a Bpifrance grant.
- Company typePrivate
- Founded2006
- HeadquartersRomainville, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pherecydes Pharma does
Pherecydes Pharma is a French private biotechnology company founded in 2006 and headquartered in Romainville, France, that develops precision phage therapy — bacteriophage-based treatments — for antibiotic-resistant bacterial infections. Its primary stated program is the PhagECOLI project, a three-year initiative targeting resistant Escherichia coli infections through a precision phage therapy approach, conducted in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA) and funded by a €2 million Bpifrance grant awarded in January 2022.
The company's product strategy centers on developing phage-based therapeutic candidates intended for use by hospitals and healthcare facilities treating patients with antibiotic-resistant infections, where conventional antibiotics have limited efficacy. Its underlying technology relies on the selection and application of phages tailored to specific resistant pathogens, with the proprietary phage-for-E. coli pipeline cited as the core technical differentiator. The company operates with a small team (11–50 employees) led by CEO Guy Charles Fanneau de La Horie, COO Thibaut du Fayet, and Scientific Director Cindy Fevre.
Pherecydes Pharma's business model is research-stage rather than commercial: it does not disclose pricing, customers, or revenue, and its funding history — roughly $19 million across five equity-style rounds from 2012 to 2018, plus the 2022 Bpifrance grant — indicates reliance on a mix of venture capital (GO CAPITAL, Ace Capital Partners, Auriga Partners, Karista, Omnes Capital, FaDièse) and non-dilutive public funding. Capital is allocated to advance its phage therapy pipeline, with monetization contingent on future clinical development, regulatory milestones, or licensing deals that are not documented in the available data.
Pherecydes Pharma firmographics
Firmographics- Name
- Pherecydes Pharma
- Legal name
- Pherecydes Pharma
- Website
- https://pherecydes-pharma.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pherecydes Pharma is a French private biotech developing precision phage therapy for antibiotic-resistant bacterial infections, primarily targeting resistant E. coli for hospital and healthcare use. It collaborates with CEA and is funded by venture capital and a Bpifrance grant.
- Ownership category
- akta.pro rank
Pherecydes Pharma industry classification
Industry- Product category
- Biopharmaceuticals (Phage Therapy)
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where Pherecydes Pharma is headquartered
LocationHeadquarters
- HQ city
- Romainville
- HQ country
- France
- HQ region
- Europe
Markets served
Pherecydes Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Pherecydes Pharma product offering
Product offeringCore offering
Pherecydes Pharma is a French biotechnology company developing precision phage therapy (bacteriophage-based treatments) to combat antibiotic-resistant bacterial infections. Its lead research program, the PhagECOLI project, focuses on creating phage-based tools and treatments targeting resistant Escherichia coli infections. The company is at the R&D stage, conducting research in collaboration with CEA and funded by Bpifrance and venture capital investors.
Product overview
Pherecydes Pharma is a biotechnology company focused on precision phage therapy for treating resistant bacterial infections. The company develops phage-based treatments, with its primary research activity centered on the PhagECOLI project funded by Bpifrance, which aims to develop new tools and treatments for resistant E. coli infections using precision phage therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- PhagECOLI A three-year research program developing precision phage therapy tools and treatments for antibiotic-resistant Escherichia coli infections, conducted in partnership with CEA and funded by a €2 million grant from Bpifrance.
Companies that use Pherecydes Pharma
Customer profileSegments1 record
Ideal customer profiles2 records
Pherecydes Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Pherecydes Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CEA (Commissariat à l'énergie atomique et aux énergies alternatives)corePherecydes Pharma collaborates with CEA on the PhagECOLI project, a three-year research initiative focused on developing new tools and treatments for resistant E. coli infections using precision phage therapy. The partnership leverages CEA's research capabilities in atomic energy and alternative energies.
Scale indicators1 record
Recent moves6 records
Expansion highlights3 records
Pherecydes Pharma competitors and assessment
Company assessmentDirect peers
- BiomX: Clinical-stage phage therapy company developing phage-based treatments for chronic and acute bacterial infections. Directly comparable to Pherecydes in modality (precision phage therapy), target indications (resistant bacterial infections), and stage of development.
- Locus Biosciences: Clinical-stage company developing engineered bacteriophage therapies, including CRISPR-enhanced phages, for antibiotic-resistant infections. Direct peer in modality, AMR focus, and clinical-stage development.
- Armata Pharmaceuticals: Clinical-stage phage therapy company developing both natural and engineered phage cocktails for resistant bacterial infections including Staphylococcus aureus and Pseudomonas aeruginosa. Direct peer in phage modality and AMR focus.
- ContraFect: Biotech developing direct lytic agents and phage-derived lysins for serious antibiotic-resistant infections. Comparable to Pherecydes in pursuing novel antimicrobial modalities against resistant bacterial pathogens.
- Eligo Bioscience: Developer of engineered phage-based therapeutics (eligobiotics) targeting specific bacterial pathogens. Comparable to Pherecydes in precision phage platform approach and focus on selectively eradicating disease-causing bacteria.
Regional players
- TechnoPhage: Portugal-based clinical-stage phage therapy developer working on personalized and fixed phage cocktails for resistant bacterial infections. Comparable to Pherecydes in modality and AMR focus, but operating primarily in Southern Europe/Portugal rather than France.
Emerging players
- Phagelux: Phage-based biotech developing therapeutic and agricultural applications of bacteriophages. Comparable to Pherecydes in phage platform technology, though with a broader agricultural/industrial portfolio alongside human health.
- Micreos: Developer of phage-based products including Gladskin for skin conditions and food-safety applications. Comparable to Pherecydes in underlying phage technology platform but currently focused on consumer/dermatology rather than systemic resistant infections.
- SNIPR Biome: Biotech using CRISPR-engineered phage and microbial approaches to precisely target bacteria. Comparable to Pherecydes in using precision phage-derived mechanisms to address resistant bacterial populations.
- Cytophage Technologies: Canadian biotech developing synthetic biology-based phage products targeting resistant bacteria in human and animal health. Comparable to Pherecydes in leveraging engineered phage approaches against AMR pathogens.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Pherecydes Pharma social profiles
Digital presencePherecydes Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pherecydes Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Pherecydes Pharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pherecydes Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pherecydes Pharma
What does Pherecydes Pharma do?
Pherecydes Pharma is a French biotechnology company developing precision phage therapy (bacteriophage-based treatments) to combat antibiotic-resistant bacterial infections. Its lead research program, the PhagECOLI project, focuses on creating phage-based tools and treatments targeting resistant Escherichia coli infections. The company is at the R&D stage, conducting research in collaboration with CEA and funded by Bpifrance and venture capital investors.
Is Pherecydes Pharma a public or private company?
Pherecydes Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pherecydes Pharma founded?
Pherecydes Pharma was founded in 2006. It employs 11 to 50 people.
Where is Pherecydes Pharma based?
Pherecydes Pharma is headquartered in Romainville, France, in the Europe region.
Who are Pherecydes Pharma's main competitors?
Direct peers on record are BiomX, Locus Biosciences, Armata Pharmaceuticals, ContraFect and Eligo Bioscience. TechnoPhage is listed as a regional player. Emerging players are Phagelux, Micreos, SNIPR Biome and Cytophage Technologies.
Does Pherecydes Pharma have an API?
No public API is recorded for Pherecydes Pharma.
What industry is Pherecydes Pharma in?
Pherecydes Pharma's product category is Biopharmaceuticals (Phage Therapy). Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.